Curis reports Q4 EPS ($2.03), consensus ($2.11)

Reports Q4 revenue $2.7M, consensus $3.02M. “The R/R PCNSL data presented at ASH highlight the potential of emavusertib in combination with ibrutinib to address a critical unmet need, for a patient population with no approved treatments, and achieve CR in patients who have failed prior BTKi therapy. The R/R AML FLT3 data highlight emavusertib’s potential to provide targeted anti-cancer activity as a monotherapy. We have also begun working with clinical investigators to initiate a Phase 1 clinical study of emavusertib as an add-on agent to the combination of azacitidine and venetoclax in the front-line setting. Finally, the study evaluating emavusertib and pembrolizumab in metastatic melanoma will explore the potential of emavusertib and IRAK4 inhibition in solid tumors,” said CEO James Dentzer. “We are encouraged by the reaction of the clinical community to the data released at ASH and are working to open additional clinical sites in the US and Europe for both the TakeAim Leukemia and Lymphoma studies.”